Charles Sigal
Direktor/Vorstandsmitglied bei VIR BIOTECHNOLOGY, INC.
Vermögen: 549 175 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 10 Jahre |
Phillip Sharp | M | 79 | 22 Jahre | |
Robert Williams | M | 75 |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA.
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | 22 Jahre |
Yvonne Greenstreet | M | 61 | 8 Jahre | |
Adrian Rawcliffe | M | 52 | 9 Jahre | |
Phil Holzer | M | 48 | 11 Jahre | |
Robert Perez | M | 59 | 7 Jahre | |
Vicki Sato | M | 75 | 18 Jahre | |
Akshay Vaishnaw | M | 61 | 18 Jahre | |
Elliot Norry | M | 61 | 9 Jahre | |
Brian Daniels | M | 65 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 24 Jahre |
Jeremy Levin | M | 70 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 6 Jahre |
Marianne de Backer | M | 55 | - | |
Dennis Ausiello | M | 78 |
National Academy of Medicine (United States)
National Academy of Medicine (United States) Miscellaneous Commercial ServicesCommercial Services The National Academy of Medicine (United States) is based in Washington and is focused on improving the health and well-being of individuals through various initiatives. These initiatives include the clinician well-being collaborative, which aims to accelerate the implementation of a national plan for health workforce well-being, and the development of a code of conduct for the use of artificial intelligence in health care. The organization also provides resources to support meaningful community engagement in health and health care programs and policies. Recently, the National Academy of Medicine announced the appointment of Mandy Cohen, a member of the organization, as the director of the Centers for Disease Control and Prevention. Additionally, the organization has released a publication celebrating 50 years of progress in biomedical science, health, and health care. | 12 Jahre |
Jeffrey Hatfield | M | 66 | 24 Jahre | |
Michael Bonney | M | 65 | 10 Jahre | |
Ron Philip | M | - | 7 Jahre | |
Noubar Afeyan | M | 60 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
John Furey | M | 59 | 8 Jahre | |
George Scangos | M | 76 | 7 Jahre | |
Robert Nelsen | M | 60 | 8 Jahre | |
Amy Schulman | F | 63 | 10 Jahre | |
Jacob Rubens | M | - |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Jeffrey Poulton | M | 56 | 5 Jahre | |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Janet Napolitano | F | 65 | 4 Jahre | |
Joshua Brodsky | M | - | 3 Jahre | |
Marc Hurlbert | M | - |
Melanoma Research Alliance
| - |
Sung Lee | M | 53 | 1 Jahre | |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Charles Albright | M | 66 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 16 Jahre |
Margaret Hamburg | M | 68 | 5 Jahre | |
Kimberly Casiano | F | 67 | 14 Jahre | |
Lawrence Alleva | M | 74 | 9 Jahre | |
Kevin Fitzgerald | M | 56 | 19 Jahre | |
Lynne Krummen | M | - | 6 Jahre | |
Hari Pujar | M | - |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 Jahre |
Sandra Leung | F | 63 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 16 Jahre |
Luk Vandenberghe | M | 47 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Jennifer Flaisher | F | - | 7 Jahre | |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 Jahre |
Kimberly McCutcheon Jablonski | F | - | 21 Jahre | |
Nicholas Simon | M | 67 |
The J. David Gladstone Institutes
The J. David Gladstone Institutes Miscellaneous Commercial ServicesCommercial Services The J. David Gladstone Institutes operates as an independent state-of-the-art biomedical research institution. The company was founded in 1979 and is headquartered in San Francisco, CA. | - |
Sona Saira Ramasastry | F | 48 | 5 Jahre | |
Michael Severino | M | 58 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 2 Jahre |
Carlo de Notaristefani | M | 67 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 20 Jahre |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Peter Kellogg | M | 67 | 1 Jahre | |
Howard Liang | M | 60 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 Jahre |
Louis Schmukler | M | - | 13 Jahre | |
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Carolyn Bertozzi | M | 57 | 1 Jahre | |
Colleen Reitan | F | 64 | 6 Jahre | |
Olivier Brandicourt | M | 68 | 4 Jahre | |
Leon Black | M | 73 |
Melanoma Research Alliance
| - |
Timothy J. Maines | M | - | 7 Jahre | |
Jeffrey Galik | M | - |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 15 Jahre |
David Pyott | M | 70 | 9 Jahre | |
Robert More | M | 56 | 8 Jahre | |
Sara Nochur | M | 63 | 18 Jahre | |
David T. Bonk | M | - |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 15 Jahre |
Ursula B. Bartels | F | 66 |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | 17 Jahre |
Christine Regan Lindenboom | F | 43 | 9 Jahre | |
Rob Aboud | M | 59 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 Jahre |
Lauren Harshman | F | - | 3 Jahre | |
Janine Rauscher | F | - |
Melanoma Research Alliance
| - |
Sancy Leachman | F | - |
Melanoma Research Alliance
| - |
Geoffrey von Maltzahn | M | 43 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Laura Richman | M | 60 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 Jahre |
Stephen Garbacz | M | 65 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | 3 Jahre |
John Mendlein | M | 64 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Margaret Anderson | F | - |
Melanoma Research Alliance
| - |
Amanda G. Eilian | F | 46 |
Melanoma Research Alliance
| 10 Jahre |
Derica Rice | M | 59 |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
James Cornelius | M | 81 | 12 Jahre | |
Giovanni Caforio | M | 59 | 24 Jahre | |
Lamberto Andreotti | M | 73 | 19 Jahre | |
Steven Altschuler | M | 70 | 10 Jahre | |
J. Goater | M | 48 | 6 Jahre | |
Peter Jakobsen | M | 61 | 19 Jahre | |
Howard Horn | M | 47 | 6 Jahre | |
Charles A. Heimbold | M | - | 20 Jahre | |
Peter R. Dolan | M | 68 | 18 Jahre | |
Liisa I. Nogelo | F | 53 | - | |
Denice Torres | F | 64 | 2 Jahre | |
Frederick Dale Fischer | M | 73 |
Purdue University
| 5 Jahre |
Rogério Vivaldi Coelho | M | 60 | 2 Jahre | |
Michel Martinus Gerardus Cup | M | 54 | 2 Jahre | |
Dominique M. Hanssens | M | - |
Purdue University
| 7 Jahre |
Jessica Fees | F | 52 | 8 Jahre | |
Stephen W. Golsby | M | 69 | 13 Jahre | |
James Noble | M | 65 | 15 Jahre | |
Robert Singer | M | 72 | 8 Jahre | |
Daniel Lynch | M | 65 | 21 Jahre | |
Michael Grobstein | M | 81 | 13 Jahre | |
Ramy Ibrahim | M | 49 | 11 Jahre | |
Armen Shanafelt | M | 64 | 9 Jahre | |
Laurie Stelzer | F | 56 | 5 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 94 | 95,92% |
Vereinigtes Königreich | 5 | 5,10% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Charles Sigal
- Persönliches Netzwerk